Sonoma Pharmaceuticals Enters Sales Agreement with Ladenburg
Sonoma Pharmaceuticals (SNOA) has entered into an At Market Issuance Sales Agreement with Ladenburg Thalmann & Co. Inc. to sell shares of its common stock, allowing for various sale methods. The agreement, effective September 26, 2025, is for an aggregate offering price of up to $2,070,463 under a SEC registration statement. Analysts rate SNOA stock as Hold with a $4.00 price target, citing strong revenue growth but challenges in profitability and cash flow. Technical analysis shows weak momentum, suggesting caution for investors.
An announcement from Sonoma Pharmaceuticals ( (SNOA) ) is now available.
On September 26, 2025, Sonoma Pharmaceuticals, Inc. entered into an At Market Issuance Sales Agreement with Ladenburg Thalmann & Co. Inc. to offer and sell shares of its common stock. This agreement allows for the sale of shares through various methods, including at-the-market offerings, with Ladenburg acting as the agent. The company is not obligated to sell shares, and the agreement will terminate upon the sale of all shares or as otherwise provided. The sales will be made under a registration statement declared effective by the SEC on November 20, 2023, with a related prospectus supplement filed on September 26, 2025, for an aggregate offering price of up to $2,070,463.
The most recent analyst rating on (SNOA) stock is a Hold with a $4.00 price target. To see the full list of analyst forecasts on Sonoma Pharmaceuticals stock, see the SNOA Stock Forecast page.
Spark’s Take on SNOA Stock
According to Spark, TipRanks’ AI Analyst, SNOA is a Neutral.
Sonoma Pharmaceuticals’ overall stock score is primarily influenced by its financial performance, which shows strong revenue growth but significant challenges in profitability and cash flow management. Technical analysis indicates weak momentum, and the valuation is concerning due to the negative P/E ratio and lack of dividend yield. These factors collectively suggest caution for potential investors.
To see Spark’s full report on SNOA stock, click here.
More about Sonoma Pharmaceuticals
Average Trading Volume: 1,287,898
Technical Sentiment Signal: Hold
Current Market Cap: $6.7M
Learn more about SNOA stock on TipRanks’ Stock Analysis page.
